partial AUCs for locally acting MR [Design Issues]

posted by Susanh – Iceland, 2020-12-04 16:14 (617 d 09:29 ago) – Posting: # 22114
Views: 2,213

Dear all,

I’m involved in the development of a MR generic drug that is locally acting in the GI tract. Despite the very helpful new EMA guideline (Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract, CPMP/EWP/239/95 Rev. 1, Corr.1*) I´m struggling with designing the BE studies to support submission in EU.

Most problematic is the justification of the cut-off for the required partial AUCs.

Does anyone have suggestions how to approach this problem?

The modified release guideline (Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms EMA/CHMP/EWP/280/96 Rev1) suggests that the cut-off should be half the dosing interval but I fear that this may not be acceptable.

Thanks in advance,

Susan

Complete thread:

UA Flag
Activity
 Admin contact
22,301 posts in 4,667 threads, 1,585 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Sunday 02:44 CEST (Europe/Vienna)

No written law has ever been more binding than
unwritten custom supported by popular opinion.    Carrie Chapman Catt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5